CN
The company takes the technical innovation of molecular detection methods as the core driving force, and focuses on the R&D and industrialization of molecular diagnostic products aiming at prevention and control of infectious diseases and genetic diseases. Uni-medica provides total solution of accurate diagnosis of infectious diseases and genetic diseases based on multi-omics technologies, including multiplex PCR,
NGS technology and flow cytometry. Uni-medica is qualified by ISO 13485 and NMPA quality control system. The pathogen molecular detection products are daily used in hundreds of hospitals, Centers for Disease Control and Prevention and Quarantine Laboratories throughout the country, providing strong support for prevention and control of infectious diseases.

Purpose

win-win

We follow the common value concept and respect the corporate culture of teamwork Attach importance to the team’s overall achievements and create synergistic value Strive to seek a win-win situation for society, customers, employees, and shareholders, and promote the sustainable development of the industry.

Keep improving

We insist on quality first, establish a production management system that meets international standards, and continuously improve manufacturing processes to ensure product quality and safety.

We respect the law of industry development, continue to accumulate and improve R&D and operating capabilities, and are committed to becoming a leading company in the industry.

Care for life

Respect and care for life, this is the source of our continuous development. We cherish the environment in which we live, and adhere to the safety and environmental protection of the manufacturing process.We actively participate in corporate citizenship activities that are beneficial to the health of the people and the progress of the community.

Innovation

Insist on independent research and development investment, and strive to achieve original breakthroughs in the field of molecular diagnostics.Committed to the application and improvement of molecular diagnostic technology and products for tumor precision medicine, to provide scientific and reliable detection basis for the precision treatment of tumor patients.

Conduct emergency research and development

Wuhan Institute of Virology, CAS

Shenzhen Uni-medica Technology Co., Ltd

In the early stage of the novel coronavirus 2019-nCoV outbreak, Uni-medica responded quickly and cooperated with the Wuhan Institute of Virology of the Chinese Academy of Sciences to conduct emergency research and development. We successfully developed the nucleic acid detection kit of novel coronavirus 2019-nCoV, which has obtained the NMPA Class III registration certificate from the National Medical Products Administration.

In order to meet the needs of novel coronavirus 2019-nCoV nucleic acid detection, Uni-medica provides a complete solution, including sampling, nucleic acid extractor and compatible nucleic acid extraction reagents, PCR detection reagents etc. The kits can once detect COVID-19, influenza A virus and influenza B virus, can also detect 15 respiratory pathogens at one time.

Message